A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)
Stopped The NAVIGATE study has been terminated due to non-safety related reasons.
Conditions
- Diffuse Large B-Cell Lymphoma
Interventions
- DRUG: bendamustine
- DRUG: navitoclax
- DRUG: rituximab
Sponsor
Genentech, Inc.
Collaborators